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Abstract 
Phytosterols are now popularly used as nutraceuticals for preventing, managing and retarding the progression of 
chronic diseases. Although several experimental studies have shown that β – sitosterol possess cardioprotective 
and hepatoprotective effects in different chronic diseased animal model, there is insufficient information on the 
biological effects of its conjugated form. This study therefore investigated the renoprotective, cardioprotective 
and osteoprotective effects of β – sitosterol glycoside (BSSG) in Cadmium Chloride (CdCl2) – induced 
hypertensive rats.  
Renal damage was induced by CdCl2 and the hypertensive groups treated with lisinopril (standard drug) at low 
dosage and BSSG at both low and high dosage. Serum urea and creatinine were quantified using appropriate 
standard methods to ascertain the integrity of the glomeruli and determine estimated Glomerular Filtration Rate 
(eGFR) while serum sodium, potassium, chloride, carbonate levels were assayed for spectrophotometrically to 
determine the extent of tubular damage and serum osmolarity. Serum alkaline phosphatase (ALP) and calcium 
levels were measured as markers of bone demineralisation. The effect on lipid profile was also determined, while 
atherogenic and coronary heart indices were calculated to determine the degree of predisposition to 
cardiovascular diseases. β – sitosterol glycoside in a concentration dependent manner significantly (p =.05) 
reduces renal damage markers (serum creatinine, blood urea nitrogen (BUN) and serum electrolytes (sodium, 
potassium, chloride and bicarbonate ions)), bone demineralisation markers (alkaline phosphatase and serum 
calcium ion) and markers of risk of atherosclerosis (total cholesterol, triacylglyceride and LDL - cholesterol). 
The results indicate that β – sitosterol glycoside elicits biological activities similar to its unconjugated form. 
Keywords: Cadmium Chloride, hypertensive, renal damage, β – sitosterol glycoside, estimated Glomerular 
Filtration Rate (eGFR) 
 
1. Introduction 
Kidney Disease (KD) is worsen by the deteriorating effects of serum calcium and phosphate overload, 
atherosclerosis, vascular calcification and hypertension which resulted from progressive renal damage (Henry 
1990; Moe et al., 2007;  Kovesdy and Kalantar – Zadeh, 2007, Ouchi and Orimo, 1990). Renal damage plays a 
primary role in the generation and progression of essential hypertension (Moe et al., 2007). Sabanayagam et al., 
2013 showed an inverse continous relationship between renal function and hypertension in an epidemiological 
survey. 
The use of drugs in the management of renal damage and associated complications has been extensively studied 
and documented. Recent advances have shown that nutritional and phytochemical therapy of renal damage and 
its complications yields better outcome. Phytosterols, which are naturally found in vegetable oils, nuts, seeds and 
grains have been investigated for their biochemical roles in chronic diseases.  β–sitosterol showed 
cardioprotective and hepatoprotective effects in CdCl2 – induced hypertensive rats (Olaiya et al., 2013: Olaiya et 
al., 2014). Its anti – atherogenic and antioxidative properties have also been reported (Awad et al., 2001). 
However, there is sparcity of data in the literature on the effects of its glycoside on renal damage and associated 
complications like hypercalcemia and risk of atherosclerosis in hypertensive rat model. Although, it has been 
suggested that conjugation of β – sitosterol might be important in their bioactivity (Olaiya et al., 2013) as 
esterification of β – sitosterol increases their solubility in the fat phase of margarines and enhances their 
desirable bioactivity (Katan et al., 2003; Spilburg et al., 2003, its amphipathic structure raises questions about 
the degree of solubility in intestinal bile salt micelles and reactivity with pancreatic enzymes (Olaiya et al., 2013). 
Therefore, this study was conducted to investigate the effects of β – sitosterol glycoside (BSSG), an active 
phytosterol abundant in Ficus asperifolia, on renal damage, hyperphosphatasemia, atherosclerosis and coronary 
heart disease indices in Cadmium Chloride – induced Chronic Kidney Disease (CKD) male Albino rats. 
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2. Materials and Methods 
Plant material, extraction and chemical analysis: β – sitosterol glycoside was isolated from fresh leaves of 
Ficus asperifolia according to the method described previously by Olaiya et al., 2013.  
Animal Treatments:  Twenty – five albino rats of Wistar strain weighing 200 – 250g were procured from 
the Central Animal House, University of Ibadan, Nigeria. They were housed at room temperature with a 12-hour 
light and dark cycle, acclimatized for a week, allowed free access to clean drinking water and fed on standard 
feed throughout the period of study. They were seperated into four different groups according to their weight, 
with five animals in each group. Renal damage was induced induced by 1 mg/kg body weight CdCl2 for  2 weeks 
(Puri, 1999) and subsequently treated by lisinopril at 1.3 mg/kg bw, low dose of BSSG (LBSSG) at 1.3 mg/kg 
bw and high dose of BSSG (HBSSG) at 2.3 mg/kg bw in the standard drug, LBSSG and HBSSG-treated rats 
respectively. Treatment lasted for additional 2 weeks. The normal and hypertensive  groups still had free access 
to clean drinking water and were given standard feed throughout the period of study. 
Biochemical assay: Urea and creatinine were quantified to ascertain the integrity of the glomeruli and determine 
estimated Glomerular Filtration Rate (eGFR) (NKF, 2003) while serum electrolyte (sodium, potassium, chloride, 
carbonate) levels were assayed for to ascertain the extent of tubular damage and serum osmolarity. Serum 
alkaline phosphatase (ALP) and calcium levels were used as markers of bone demineralisation. The lipid profile 
was also assayed as a metabolic system fuction test, while atherogenic and coronary heart indices were 
calculated to determine the degree of predisposition to cardiovascular diseases. 
Estimation of serum calcium level was done using colorimetry technique. Serum sodium and potassium ions 
were estimated by Flame Emission Spectrophotometry using SEAC FP 20. Serum bicarbonate levels was 
estimated as described by Meites and Faulkner, (1962). Estimation of Serum Chloride was assessed by the 
method described by Mather et al., (1982). Estimation of serum triglycerides, Total Cholesterol, HDL – 
Cholesterol and LDL – C holesterol levels were done by standard kit methods based on CHOD-PAP colorimetric 
method, and the analyses carried out following the standard protocols. Serum creatinine levels were determined 
according to the standard kit method of Bartels et al., (1972). Serum urea levels and ALP enzyme activities were 
measured using standard kit methods. 
Statistical analysis: Data collected were expressed as mean ± SEM and analysed using analysis of variance 
(ANOVA). Least Significant Difference (LSD) were used as a test of significance within treatments. p =.05 
indicated statistical significance unless otherwise stated. 
 
3. Results  
Serum creatinine and blood urea nitrogen (BUN) levels and estimated GFR 
The increased serum creatinine and BUN levels in the hypertensive rats was reversed significantly (p =.05)  in 
the lisinopril, LBSSG and HBSSG - treated hypertensive rats as shown in Table 1. In addition, there was a 
stepwise reduction in creatinine and BUN levels in the LBSSG and HBSSG - treated hypertensive rats. This was 
evident in the improved eGFR of the lisinopril, LBSSG and HBSSG treated hypertensive rats when compared 
with the hypertensive rats. 
Serum electrolyte 
Table 2 shows that there was a significant (p = .001) increase in sodium and potassium levels in rats with 
untreated hypertensive group when compared with the control (normal rats). However, a significant (p = .001) 
decrease in sodium levels in the lisinopril, LBSSG, HBSSG treated hypertensive rats was observed when 
compared with the untreated hypertensive rats. Also a significant reduction (p=.001) in the chloride levels of 
Lisinopril and LBSSG treated hypertensive rats was observed in comparison with the untreated hypertensive rats. 
There was no significant difference (p = .001) on bicarbonate levels. An increase in the urea, sodium and 
potassium levels in the untreated hypertensive rats suggestively increases the osmolarity of the blood which 
might directly affect the water retention capacity of the body by the kidney. This impaired renal function 
contributes to a major extent to the hypertension condition in the CdCl2 treated rats. However, treatment with the 
phytosterol significantly restore this renal function.  
Serum alkaline phosphatase activity and calcium levels 
High activity and level of serum alkaline phosphatase and calcium respectively in the hypertensive rats which 
was significantly reversed (p =.05)  in the LBSSG and HBSSG treated hypertensive rats as shown in Table 3 
suggest that the β – sitosterol glycoside could suficiently reduced and minimise the extent of bone 
demineralisation in rats with sufficient renal damage. In addition, a stepwise reduction in serum alkaline 
phosphatase activity and calcium levels in the LBSSG and HBSSG treated hypertensive rats was observed.  
 
Lipid profile and atherosclerosis index 
In Table 4, lisinopril, LBSSG and HBSSG significantly reduced (p = .05) the total cholesterol, triacylglycerides, 
HDL – cholesterol and LDL – cholesterol in the treated hypertensive rats when compared with the untreated 
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hypertensive rats. A progressive reduction was observed in the LBSSG and HBSSG treated hypertensive rats. 
This significant reduction in the lipid profile was evident in a stepwise reduction (p = .05) in the risk of 
formation of atherosclerotic plague in the treated hypertensive rats. 
 
4. Discussion  
Creatinine clearance test levels which has become the most popular test for measuring the eGFR is extremely 
useful in determinig the capacity of the glomerular to adequately perform the function of ultrafiltration in the 
kidney. An increase in plasma or serum creatinine levels implies impaired glomerular function. Although urea 
clearance test is not a measure of the glomerular filtration rate, it is an index of of overall renal function. The 
reduction in creatinine and BUN levels in the β – sitosterol glycoside treated hypertensive rats signifies that it 
could ameliorate renal damage and probably restore overall renal functions. In addition, serum electrolyte tests is 
commonly used as a indicator of the osmoregulatory function of the kidney. Also an increase in the serum 
concentration of these electrolytes signifies an increase in the osmolarity of the body fluids (Agada and Briade, 
2009) and by implication the kidney sets up a system that leads to high blood pressure which if untreated results 
in essential hypertension and hyperthropy of the heart tissue.  
A reduction in some of the electrolytes in the β – sitosterol glycoside treated hypertensive rats implies that this 
might be a major pathway in which it mitigate hypertension in the hypertensive rat model. Moreover, a 
concentration dependent  increase in the protective effects of β – sitosterol glycoside in the hypertensive treated 
rats shows that it has little or no toxic effect on the wellness of the rats. 
A build – up of cholesterol in blood vessel walls leads to atherosclerosis which increases in pathological 
conditions like hypertension (Shanmuganayagam et al., 2007; Olaiya et al., 2013). Increased level of total 
cholesterol, triacylglycerides and LDL – cholesterol speed up atherosclerosis and are major risk factors of 
cadiovascular diseases (NCEP, 2002). Also, an intense formation of atherosclerotic plagues predisposes an 
individual hypertension. Atherosclerosis index gives a clue to the predisposition of an individual to formation of 
atherosclerotic plague and risk of coronary heart diseases. A reduction in the lipid profile and atherosclerosis 
index by β – sitosterol glycoside suggests that this might be another pathway although not a major one in which 
it reduces the predisposition of an individual to hypertension. 
A major event that characterises kidney diseases is bone demineralisation. Several factors are involved in bone 
demineralisation and low bone density in individuals with kidney disease. However, hyperphosphatasemia 
(increase in alkaline phosphatase active) and hypercalcemia (serum calcium overload) are indicators of bone 
demineralisation (Catapano, 1997). They are also factors in the calcification of atherosclerotic plagues (Kovesdy 
and Kalantar-Zadeh, 2008). Alkaline phosphatase catalyses the degradation of pyrophosphate (an inhibitor of 
calcification and bone demineralisation) (Kovesdy and Kalantar-Zadeh, 2008) thereby leading to an overload of 
phosphate in the blood. This overload of blood phosphate and calcium leads to the formation of hydroxylapetite 
which is deposited on the atherosclerotic plague and other smooth muscle cells. Uncontrolled formation and 
deposition of hydroxylapetite accelerate hypertension and cardiac hyperthrophy (Ouchi and Orimo, 1990). β – 
sitosterol glycoside reduces the activities of alkaline phosphatase and calcium levels in the hypertensive treated 
rats. Antihypercholesterolemic potentials of phytosterols and plant extracts had been investigated (Olaiya and 
Omolekan, 2013; Omolekan and Olaiya, 2013; Olaiya et al., 2013: Olaiya et al., 2014). In hypercholesterolemic 
patients, phytosterols showed 44 – 45% decrease in cholesterol (Nature life, 2005). 
The results in the present study indicate that β – sitosterol glycoside elicit renoprotective, cardioprotective and 
osteoprotective activities irrespective of their conjugation to a glucose moiety. However, molecular studies are 
needed to further understand the mechanism by which β – sitosterol glycoside elicit these activities. This is of 
importance in the therapeutic applications of β – sitosterol glycoside in chronic diseases in which the scientific 
world has not found a particular and less expensive therapy for. 
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Table 1: Effects of Lisinopril, LBSSG and HBSSG on serum creatinine, BUN levels and eGFR of normal and 
hypertensive rats 
Groups Creatinine (μmol/l) BUN (mmol/l) eGFR (ml/min) 
Control  1.57 ± 0.25 40.5 ± 12.02 31.48 
Hypertensive  1.68 ± 0.05 * 46.67 ± 3.86 * 29.42  
Hypertensive + lisinopril 1.35 ± 0.13 ** 42.50 ± 4.95 ** 36.61 ** 
Hypertensive + LBSSG 1.60 ± 0.20 ** 36.00 ± 6.00 ** 30.89 ** 
Hypertensive + HBSSG 1.47 ± 0.35 **, *** 27.00 ± 5.66 **, *** 33.63 ** 
 
Values expressed as means ± SEM, n = 5  
* = statistical significant when compared with control (p = .05). 
** = statistical significant when compared with untreated hypertensive group (p = .05). 
*** = statistical significant when compared with hypertensive + LBSSG group (p = .05). 
 
 
Table 2: Effects of Lisinopril, LBSSG and HBSSG on serum electrolytes of normal and hypertensive rats 
Groups Sodium  (mmol/l) Potassium  
(mmol/l) 
Chloride  
(mmol/l) 
Bicarbonate 
(mmol/l)  
Control  145.00 ± 1.00 6.77 ± 0.25 113.00 ±1.73 18.67 ± 0.58 
Hypertensive  146.00 ± 2.63 * 6.43 ± 0.57 * 112.75 ± 1.80 19.75 ± 1.50  
Hypertensive + lisinopril 141.75 ± 1.71 ** 5.70 ± 0.77 ** 108.75±2.06 ** 19. 50 ± 1.20 
Hypertensive + LBSSG 145.60 ± 1.60 ** 6.47 ± 0.06 110.33±1.53 ** 20.00 ± 0.00 
Hypertensive + HBSSG 143.33 ±4.93 **, *** 6.60 ± 0.78 112.67 ± 3.06 18.00 ± 1.00 
 
Values expressed as means ± SEM, n = 5  
* = statistical significant when compared with control (p = .001). 
** = statistical significant when compared with untreated hypertensive group (p = .001). 
*** = statistical significant when compared with hypertensive + LBSSG group (p = .001). 
 
 
Table 3: Effects of Lisinopril, LBSSG and HBSSG on serum alkaline phosphatase activity and calcium level of 
normal and hypertensive rats 
Groups ALP (IU) Calcium (mmol/l) 
Control  135.30± 25.77 7.97 ± 0.31 
Hypertensive  145.00±33.22 * 8.67 ± 0.38 * 
Hypertensive + lisinopril 144.10 ± 16.28 8.85 ± 0.38 
Hypertensive + LBSSG 138.40±46.67 ** 8.53±0.31 ** 
Hypertensive + HBSSG 134.30±32.67 ** 8.40±0.20 ** 
 
Values expressed as means ± SEM, n = 5  
* = statistical significant when compared with control (p = .01). 
** = statistical significant when compared with untreated hypertensive group (p=.01). 
*** = statistical significant when compared with hypertensive + LBSSG group (p= .01). 
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Table 4: Effects of Lisinopril, LBSSG and HBSSG on lipid profile and atherosclerosis index of normal and 
hypertensive rats 
Groups Total Cholesterol TAG HDL – 
cholesterol   
LDL – Cholesterol Atherosclerosis 
index 
Control  56.00 ± 6.36 79.33 ± 43.66 22.67 ± 4.04 14.65 ± 5.20 2.18 
Hypertensive  77.5 ± 2.12 * 125.33±18.04 * 35.00 ± 2.65 * 17.43 ± 2.39 * 2.21 * 
Hypertensive + 
lisinopril 
59.00 ± 6.93 ** 85.00 ± 7.02 ** 28.50±4.65 ** 13.50 ± 5.79 ** 2.07 ** 
Hypertensive + 
LBSSG 
67.5 ± 2.12 ** 105.33±6.51 ** 33.00±5.57 ** 13.43 ± 3.84 ** 2.04 ** 
Hypertensive + 
HBSSG 
60.75 ± 1.53 ** 84.5 ± 0.71 ** 30.5 ± 4.99 ** 13.35 ± 3.26 ** 1.99 ** 
 
Values expressed as means ± SEM, n = 5  
* = statistical significant when compared with control (p = .05). 
** = statistical significant when compared with untreated hypertensive group (p = .05). 
*** = statistical significant when compared with hypertensive + LBSSG group (p = .05). 
  
 
